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Abstract
 
Substantial evidence indicates that mitochondria are a major checkpoint in several pathways
leading to neuronal cell death, but discerning critical propagation stages from downstream con-
sequences has been difficult. The mitochondrial permeability transition (mPT) may be critical
in stroke-related injury. To address this hypothesis, identify potential therapeutics, and screen
for new uses for established drugs with known toxicity, 1,040 FDA-approved drugs and other
bioactive compounds were tested as potential mPT inhibitors. We report the identification of
28 structurally related drugs, including tricyclic antidepressants and antipsychotics, capable of
delaying the mPT. Clinically achievable doses of one drug in this general structural class that
inhibits mPT, promethazine, were protective in both in vitro and mouse models of stroke.
Specifically, promethazine protected primary neuronal cultures subjected to oxygen-glucose
deprivation and reduced infarct size and neurological impairment in mice subjected to middle
cerebral artery occlusion/reperfusion. These results, in conjunction with new insights provided
to older studies, (a) suggest a class of safe, tolerable drugs for stroke and neurodegeneration;
(b) provide new tools for understanding mitochondrial roles in neuronal cell death; (c) demon-
strate the clinical/experimental value of screening collections of bioactive compounds enriched
in clinically available agents; and (d) provide discovery-based evidence that mPT is an essential,
causative event in stroke-related injury.
Key words: caspases • cell death • apoptosis • antidepressants • antipsychotics
 
Introduction
 
Evidence from multiple systems has established mitochon-
dria as a critical checkpoint in cell death (1–9). In particular,
both caspase-dependent and caspase-independent cell death
cascades in the central nervous system (CNS) appear to
require mitochondrial release of protein factors such as cy-
tochrome 
 
c
 
, AIF, and SMAC/Diablo (10–14). The basic
mechanisms underlying the release of these factors remains
unclear (15, 16). Induction of the mitochondrial perme-
ability transition (mPT) has been one proposed mechanism
underlying this release.
Induction of an mPT has been linked to cytotoxicity after
pathological insults such as viral-induced cytotoxicity (17,
18), cardiac ischemia-reperfusion injury (8, 19), stroke and
excitotoxicity (6, 7, 20–22), trauma (23), and hypoglycemia
(24). mPT, which has been defined primarily using mito-
chondria isolated from heart and liver, is the opening of
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2
 
, phospholipase A
 
2
 
; SAR, structure–activity relationship. 
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pores in the inner mitochondrial membrane, resulting in
free diffusion of solutes 
 
 
 
1.5 kD, destroying the proton
gradient, generating reactive oxygen species, and releasing
accumulated Ca
 
2
 
 
 
 (25–28) as well as cytochrome 
 
c
 
, AIF,
and SMAC/DIABLO (12, 29–32). These findings link
mPT to the release of the direct mediators of downstream
caspase-dependent and -independent cell death pathway. A
comparison of observations in isolated liver and brain mito-
chondria suggest that “mPT-like” events do occur in brain
mitochondria, even if the characteristics of the brain mPT
differ in detail from that which occurs, for example, in liver
mitochondria (6, 20, 24, 29).
The specific case of cell death resulting from stroke is as-
sociated with pathophysiological changes/conditions that,
acting in concert, are predicted, largely on the basis of ex-
periments in isolated liver mitochondria, to favor induction
of the mPT. These factors include high Ca
 
2
 
 
 
, increases in
reactive species, free inorganic phosphate, and activation of
upstream protein factors, such as bid and bax (33). Most
(20, 29, 34–37), but notably not all (5, 38), studies in cul-
tured cells isolated CNS mitochondria, and experimental
models of acute neurological injury (e.g., ischemia/reper-
fusion) are consistent with the existence of an event analo-
gous with the mPT in the CNS.
However, it remains unclear whether mPT is on the
causative pathway of cell death, or whether it is a down-
stream effect related to overall cellular collapse, which in-
cludes, for example, oxidative damage to components of the
oxidative phosphorylation system (39, 40). Although neuro-
protection mediated by cyclosporine A (CsA) was initially
cited as evidence for causal involvement of mPT in ischemic
injury (20, 21), this is now appreciated to be problematic as
CsA also affects calcineurin, the blockade of which itself has
been shown to be neuroprotective (41). Similar “lack of
specificity” arguments hold for minocycline and taurour-
sodeoxycholic acid. Minocycline is a second generation tet-
racycline antibiotic known to be protective in models of
stroke (42, 43), spinal cord injury (44, 45), and neonatal hy-
poxia-reperfusion injury (46). Although our recent work
links minocycline to prevention of mPT-mediated release of
mitochondrially sequestered protein factors that facilitate
both caspase-dependent and -independent cell death path-
ways (29, 47), other actions of minocycline have been iden-
tified (42, 43), and the use of minocycline to build a case for
mPT involvement awaits a more mechanistic analysis of the
actions of minocycline. Tauroursodeoxycholic acid is an en-
dogenous bile acid that protects against stroke, but it is
known to modulate activities in three major pathways in-
volved in ischemic damage, including mPT, activity of bcl-2
family members, and signal transduction pathways (48).
Likewise, support for an obligate role for tbid activation in
ischemia-reperfusion injury now exists (49), but evidence
exists that tbid facilitates both mPT induction (33) and
mPT-independent release of mitochondrially sequestered
pro-apoptogenic factors (16, 50). Similar to the clear evi-
dence for an obligate role of tbid activation, there is also ev-
idence of the required Ca
 
2
 
 
 
 deregulation, but there is at least
one line of experimentation using cultured cerebellar gran-
ule cells that argues against an early role for mPT induction.
Studies of excitotoxic injury in these cells often point to the
critical event being a delayed, mitochondrially mediated de-
regulation of cytoplasmic calcium as the critical failure event
at the level of individual cells (5). The mechanisms that fol-
low kainite exposure seem to differ from those that follow
NMDA exposure (51) and neither seems to involve mPT as
a critical decision point check (51, 52). It is worth noting
that these studies are conceptually difficult to extend in vivo
as these cells are comparatively resistant to ischemia.
The best direct test of the hypothesis that mPT lies on the
causative pathway of clinically relevant cell death comes from
the studies of 
 
N
 
-Met-Val-CysA, a nonimmunosuppressive
analogue of CsA reputed not to interact with calcineurin.
This compound reduces infarct size in a rat model of tran-
sient focal ischemia (6). This data is strengthened somewhat
by evidence that the effects of CsA on protection against in-
farction may extend temporally in time from the effects of
the calcineurin inhibitor FK506 (53). However, the universal
acceptance of mPT involvement in stroke remains limited, in
part because of the reliance on data from a single drug (54),
and the limited availability and characterization of its ana-
logue. Furthermore, CsA is not viewed as a long-term medi-
cal option, as the blood brain must be opened (e.g., by nee-
dle puncture) for any therapeutic efficacy (53).
Thus, there is a need to show that other characterized
agents can modulate mPT induction and protect against ce-
rebral infarction, both to answer this central mechanistic
question in the pathogenesis of stroke-related neuropathol-
ogy and to help reduce its clinical effects. The work pre-
sented here addresses these issues.
Given the potential clinical impact of drugs that inhibit
mPT, we screened a collection of 1,040 bioactive com-
pounds for their ability to delay mPT induction in isolated
rat liver mitochondria. This collection was primarily com-
posed of clinically approved drugs that could readily be
moved to late-stage preclinical trials and then into clinical
trials (55, 56). The remainder of the collection largely con-
sisted of some analogues of these drugs, and other known
bioactive agents (including natural products, toxins, and
controlled substances). Thus, in contrast with large, high,
and ultra-high throughput screens of combinatorial librar-
ies, this screen emphasized a much smaller compound set
focused on known, bioactive compounds, most of which
were FDA approved and, thus, are more likely to be mini-
mally toxic and potentially rapidly available for clinical us-
age. Screening of this collection was blind and was de-
signed to identify compounds that act independently of
antioxidant activity or ability to chelate Ca
 
2
 
 
 
 approaches
that have been taken previously by others.
The data obtained (a) provide discovery-based validation of
the mPT as lying on the causative pathway of stroke-related
neurologic injury, (b) identify potential therapeutics that are
already FDA approved, and (c) demonstrate the potential
utility of coupling mechanism-based screening with libraries
enriched in well-characterized, clinically available agents. 
Stavrovskaya et al.
 
213
 
Materials and Methods
 
Chemicals.
 
The drug collection screened was the National In-
stitute of Neurological Disorders and Stroke Custom Collection
from MicroSource Discovery Systems, Inc. Ultra-pure sucrose was
obtained from ICN Biomedicals. All other compounds, of the
highest purity available, were obtained from Sigma-Aldrich. All
substrates used in mitochondrial respiration experiments were dis-
solved in respiration buffer (see Fig. 2) and brought to neutral pH.
 
Mitochondrial Isolation.
 
Liver mitochondria were isolated from
 
 
 
4-mo-old male Fischer 344 
 
 
 
 Brown Norway F
 
1
 
 rats by differ-
ential centrifugation using sucrose-based buffers (29). Animal
protocols were approved by the Institutional Animal Care and
Use Committees of Weill Medical College of Cornell University.
 
Library Screening and Dose Response Analysis.
 
Assays were run
in 265 mM sucrose, 2.6 mM Hepes, pH 7.35, and 2.1 mM
K-PO
 
4
 
, pH 7.35. Incubations included 10 mM 
 
 
 
-ketoglutarate, 5
mM glutamate/malate, or 5 mM succinate and CaCl
 
2
 
 (10 
 
 
 
M for
 
 
 
-ketoglutarate and 20 
 
 
 
M for glutamate/malate and succinate) to
energize mitochondria (57). Drugs were screened at 10 
 
 
 
M. Final
mitochondrial concentration was 0.75 mg protein/ml. Swelling
was monitored by following changes in absorbance at 540 nm and
660 nm (A
 
540,
 
 A
 
660
 
) for 1.5 h using a SpectraMax 250 Plate Reader
(Molecular Devices; reference 57). For secondary dose response
analysis, 2 out of 27 plates and 
 
 
 
3% of remaining data were ex-
cluded as technical outliers by visual inspection. Thus, the dose
response data on these agents is based on 7–9 replicates (Fig. S1
and Supplemental Materials and Methods, available at http://
www.jem.org/cgi/content/full/jem.20032053/DC1). 
 
Simultaneous Measurement of 
 
  
 
, Oxygen, Swelling, and Ca
 
2
 
 
 
Transport.
 
Simultaneous measurement of 
 
  
 
, oxygen con-
sumption, swelling, and Ca
 
2
 
 
 
 transport was accomplished using a
four-channel respiration system (29, 58). Buffers and additions are
described in the figure legends. Oxygen uptake, membrane po-
tential, and Ca
 
2
 
 
 
 was measured using Clark, TPP
 
 
 
, and Ca
 
2
 
 
 
-
sensitive electrodes, respectively. Absorbance (A
 
660
 
) was mea-
sured using a diode. All experiments were performed in triplicate.
Representative plots are shown in the paper.
 
Phospholipase A
 
2
 
 (PLA
 
2
 
) and Calmodulin Inhibition.
 
The abil-
ity of the heterocyclics to inhibit PLA
 
2
 
 was determined based on
a modification of the method of Meshulam et al. (59). The ability
of the heterocyclics to inhibit calmodulin function was assessed
by examining the effect of these agents on calmodulin-dependent
calcineurin activity (Upstate Biotechnology). Detailed methodol-
ogies are presented in the supplemental material.
 
Neurotoxicity Studies on Cultured Primary Cerebrocortical Neurons.
 
Neurotoxicity studies were conducted as described previously
(60). Cerebral cortex of mouse embryos at day 15 (E
 
15
 
) were
freed from meninges and separated from the olfactory bulb and
hippocampus. Trypsinized cells were suspended in medium (neu-
robasal medium with 2% [vol/vol] B27 supplement/2 mM gluta-
mine/100 U/ml penicillin) and streptomycin (GIBCO BRL) and
seeded at a density of 2 
 
 
 
 10
 
4
 
/cm
 
2
 
 on polylysin-coated dishes.
Cells were used for experiments on day 7 of culture. Cell death
was evaluated by the lactate dehydrogenase (LDH) release assay.
 
Stroke Studies in Mice.
 
Middle cerebral artery occlusion/reper-
fusion studies were conducted as described previously (60, 61).
All animal experiments were conducted in accordance with the
National Institutes of Health and institutional guidelines. Male
C57/B6 (Charles River Laboratories) mice weighing 18–29 g
were housed in standard temperature (22 
 
 
 
 1
 
 
 
C) and in a light-
controlled (light on 07:00–21:00) environment with ad libitum
access to food and water. Weight of animals undergoing stroke
were restricted to 
 
 
 
22 g. Animals undergoing stroke were ran-
domized to two groups: untreated (i.p. injection with 0.9% sa-
line) and treated (i.p. injection with promethazine solution).
Weight of animals undergoing sham operations was liberalized to
18–29 g.
 
Surgery and Occlusion. 
 
Immediately before surgery, each
mouse was anesthetized with 2% isoflurane (70% N
 
2
 
O/30% O
 
2
 
).
During surgery, isoflurane was lowered to 1%. A midline incision
was made in the neck and the right common carotid artery was
dissected. The right MCA was occluded with a 7-0 nylon filament
after permanent ligation of the external carotid artery and tempo-
rary ligation of the common carotid artery (61, 62). Right MCA
occlusion was defined as a 
 
 
 
90% drop of peak velocity measured
by the laser Doppler flowmetry drop (63). The occluding filament
was removed after 120 min. Body temperature was monitored and
regulated using a heating pad. Sham operations consisted of the
same duration and concentration of anesthesia, midline incision,
doppler probe insertion over right temporal bone, and dissection
of common carotid artery, but no manipulation of the common
carotid artery or external carotid artery. The surgeon was blinded
to treatment group. All mice were killed at 24 h after perfusion.
Experiments were in accordance with protocols approved by the
Harvard Medical School Animal Care Committee.
 
Drug Treatment. 
 
Both treated and control groups received
two i.p. injections: the first was delivered 1 h before ischemia,
and the second was delivered 12 h later. Each i.p. dose was 10
mg/kg (in 0.5 ml) of promethazine dissolved in 0.9% NaCl or an
equal volume of buffer alone (64).
 
Determination of Infarct Volume. 
 
After 24 h of reperfusion, the
mice were killed. The brains were quickly removed and chilled
for 2 min. The cerebellum was removed. Coronal sections (2-mm
thick; 
 
n
 
 
 
 
 
 6) were cut in a craniotome. Each slice was immersed
in a saline solution containing 20 mg/cc of 2,3,5-triphenyltetra-
zolium chloride (Sigma-Aldrich) at 37
 
 
 
C for 30 min. After stain-
ing, each slice was scanned by an HP scanjet 4200C. The unstained
areas in each hemisphere were quantified, and the ischemic area
per slice 
 
 
 
 left (normal side) 
 
 
 
 right (ischemic side) (42, 62, 65).
The infarct volume was calculated by summing up the infarcted
areas in the six slices and calculating the volume for a cylinder
(area 
 
 
 
 height).
 
Neuro Exam Scores. 
 
Scores follow Bederson et al. (66). 0, no
neurological deficits; 1, failure to extend the left forepaw; 2, cir-
cling to contralateral side; and 3, loss of ability to walk or righting
reflex. The examiner was blinded to treatment group.
 
Online Supplemental Material. 
 
Online supplemental material
includes the following. Details on the library screening methods,
primary results, and the validation of the methods used (Figs. S1
and S2). Discussion of preliminary structure–activity relationship
(SAR) analysis. Graphic comparisons between inhibition of PLA
 
2
 
activity and calmodulin activity and protection against mPT
activation (Fig. S3). Methods for these supplemental tests and
additional literature citations for activity of related agents
against spinal cord injury, sepsis and cardiac, liver and kidney
damage (e.g., from ischemia-reperfusion). Online supplemental
material is available at http://www.jem.org/cgi/content/full/
jem.20032053/DC1.
 
Results
 
Library Screen. 
 
Given the potential clinical impact of
drugs that inhibit mPT, we screened a library of 1,040 bio- 
Available Drugs Protect Mitochondria and Reduce Stroke-induced Pathology
 
214
active compounds for their ability to delay mPT induction
in isolated rat liver mitochondria (Fig. 1, Fig. S1, and Sup-
plemental Materials and Methods). Of the 23 compounds
showing “moderate” protection in the initial screen, 2
were known mPT inhibitors: tamoxifen and trifluoperazine
(both “positive controls”).
Figure 1. Heterocyclics mediate dose-
dependent protection that is robust and not
related to therapeutic class. (A) Drug struc-
ture, name, and therapeutic class of each
heterocyclics-related structure in the initial
compound library. Compounds ranked best
to worst (from left to right and top to bottom)
based on the data in B. As one measure of
potential clinical utility, human use approval
was examined using a list of U.S. FDA-
approved drugs. Drugs currently in clinical
use (23 out of 32) have no abbreviations
after their name. Where abbreviations appear
after the drug names, they refer to the fol-
lowing: not used in humans (NHU; 1 of 32);
used in humans, current status and countries
of acceptance uncertain (HU; 4 out of 32);
and FDA-approved but believed discontinued
(DSC; 4 out of 32). (B) Relative areas under
the absorbance curve for the 32 heterocyclics
studied at 30  M. Bars are color coded by
each drug’s therapeutic class. Minimal pro-
tection was observed at concentrations
 1  M, and these data were pooled with
the no-drug controls to serve as the control
dataset. Total control dataset, n    1207.
Area relative to control, 1.14   0.48 (mean  
SD). The mean coefficient of variation (CV) for individual experiments was 32%, and the mean CV within a specific challenge was 15%. Protection
observed was statistically significant at P   0.05 for 28 out of 32 agents (see Table I). Compounds were assayed in triplicate at seven concentrations (30,
10, 3, 1, 0.3, 0.1, and 0.03  M) against three different challenges (50  M Ca2 /2.5 mM K-PO4, 25  M Ca2 /5 mM K-PO4, 25  M Ca2 /2.5 mM
K-PO4/100  M tert-butyl hydroperoxide). Loss of absorbance (i.e., induction of PT) was followed as described in Materials and Methods, and areas
under the curve were determined. The increased area under the curve is proportional to delay of PT induction. The area under the curve is expressed as
a ratio to the area under the control curves on the same plate. For each drug, n   7–9. Thick horizontal lines show mean and mean  1 SD. 
Stavrovskaya et al.
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Potency Studies of Heterocyclic, Tricyclic, and Phenothiazine-
derived (HTPD) mPT Inhibitors. 
 
Inspection of the structures
of the 23 compounds that showed moderate protection re-
vealed that trifluoperazine and 12 additional compounds were
from a specific subclass of heterocyclics and their structural
analogues, a major class of psychotropic drugs used clinically
since the 1950’s. These included tricyclic antidepressants
and phenothiazine-derived antipsychotics. The compound
library was reexamined to identify potential analogues that
had been considered inactive. This was done both to deter-
mine if these were initially false negatives and to identify
structurally related, but inactive compounds for SAR analy-
sis (Supplemental Materials and Methods). Retrospective
analysis showed that 32 compounds in the collection had a
common chemical motif that includes or approximates the
tricyclic/heterocyclic backbone (with either a six- or seven-
member central ring; Fig. 1 A). Each of these 32 com-
pounds was reassayed against three models of mPT induc-
tion and ranked according to the resistance it conferred to
induction (Fig. 1 B). Challenges were combined to give a
single score reflecting overall protection against mPT (Fig. 1
B and see Table I). Of the experimental set of 32 com-
pounds, 28 gave statistically significant protection at con-
centrations 
 
 
 
30 
 
 
 
M. Of these 28, 21 (75%) and 12 (43%)
were protective at 10 and 3 
 
 
 
M, respectively. Analytical
controls for dose and scoring method are provided as sup-
plemental material (Fig. S2, A and B, available at http://
www.jem.org/cgi/content/full/jem.20032053/DC1).
Searches of the scientific literature and the US FDA-
approved drug list indicate that 23 of these 32 agents are in
clinical use, and 4 others are approved but no longer in ac-
tive clinical use. Four others were approved, at least for
clinical trials, in at least one country. Only one (methio-
thepin) appears not to have been used on humans (Fig. 1 A).
 
HTPD mPT Inhibitors Do Not Alter Basic Mitochondrial
Physiology. 
 
Mitochondrial physiological parameters were
assessed to determine whether these heterocyclics and their
structural analogues interfered directly with other mito-
chondrial functions, and whether such interference might
underlie their inhibition of the mPT due to a nonspecific
effect on aspects of mitochondrial function needed for the
assay to measure mPT induction. Specifically, we tested
three major physiological functions of mitochondria as fol-
lows: their ability to respire, their ability to retain a mem-
brane potential (
 
  
 
), and their ability to take up and retain
exogenous calcium. Representative data under conditions
favoring mPT induction are shown in Fig. 2. Compounds
shown represent some of the structural and functional
diversity present in the heterocyclic compound class (flu-
fenazine and promethazine [antihistaminics]; methiothepin
[serotonin modulator]; and clomipramine [antidepressant]).
At 10 
 
 
 
M, these compounds protected against mPT induc-
tion (Fig. 2 D) without apparent effects on initial oxygen
consumption before mPT induction (Fig. 2 A), Ca
 
2
 
 
 
 trans-
port (Fig. 2 B), or resting or recovered 
 
  
 
 (Fig. 2 C).
These results suggest that the protection against PT is not
Figure 2. Heterocyclics delay mPT induction in iso-
lated liver mitochondria without impairing mitochondrial
physiology. TPP  was titrated into buffer to enable
construction of standard curves (0–300 s). Succinate-
energized mitochondria were added to buffer (with 10
 M of drugs, where noted) within 10–20 s of the
graph’s origin (300 s). 100  M Ca2  was added where
noted, and the curves were standardized at this point.
(A) Oxygen consumption was measured by Clark elec-
trode. Oxygen concentration in buffer decreases as signal
decreases. (B) Ca2  transport measured by Ca2 -selective
electrode. Ca2  in buffer increases as signal increases.
(C)    measured using a TPP  electrode.    decreases
as signal increases. TPP  uptake was determined by
comparison with standard curve after correction for
shift in electrode signal induced by drugs. Mitochondria
appear to take up equal levels of TPP  in the presence
and absence of drug and restore TPP  and Ca2  levels
after recovering from Ca2  pulse, suggesting that these
drugs have minimal or no direct effects on   .
Changes in    consistent with the slight increases in
respiration (equivalent to  5% of maximally uncoupled
mitochondria) observed with some drugs is likely below
the limit of detection. (D) Swelling (absorbance) moni-
tored by a light emitting diode at A660. Mitochondrial
are more swollen when signal decreases. Assay in 300
mM sucrose, 2.5 mM K-PO4, 3 mM Hepes, pH 7.2,
and 5 mM succinate. Experiments were stopped after
oxygen was consumed.Available Drugs Protect Mitochondria and Reduce Stroke-induced Pathology 216
associated with any overt mitochondrial toxicity. The ad-
dition of the high Ca2  dose induces mPT in the control
sample; drug-treated samples are protected against MPT.
Indeed,    is maintained, swelling is prevented, and cal-
cium is sequestered until the oxygen in the chamber has
been consumed. The protective effects of these drugs at
the level of purified mitochondria reflect a novel cellular
site of action for these drugs, and the ability of these com-
pounds to inhibit the mPT suggests that they represent
potential inhibitors of some pathways of apoptosis and
necrosis.
HTPD PT Inhibitors Do Not Mediate Induction by Inhibit-
ing PLA2 or Calmodulin.  One heterocyclic/phenothia-
zine, trifluoperazine, has been identified as an mPT inhibitor
and has been shown to be protective against ischemia-
reperfusion injury in multiple models. Trifluoperazine can
inhibit both PLA2 (67) and calmodulin (68). Both of these
activities have been hypothesized to be protective against
mPT. In particular, PLA2 inhibition has received substantial
attention, despite some evidence arguing that it is not the
mechanism by which trifluoperazine protects against mPT
(67). Literature analysis suggested that other tricyclics and
phenothiazines might also inhibit PLA2 or calmodulin ac-
tivity. Therefore, we assayed the capacity of each tricyclic
in the library to inhibit PLA2 or calmodulin at concentra-
tions from 1–300  M. The ability to inhibit either PLA2 or
calmodulin did not correlate with the ability to inhibit
mPT in the compound set tested (PLA2: r2   0.04 at 100
 M; calmodulin: r2   0.02 at 300  M; see Table I and
Fig. S3, available at http://www.jem.org/cgi/content/full/
jem.20032053/DC1).
Physiological Studies of HTPD PT Inhibitors.  Because of
the role of apoptosis in stroke-mediated pathology, the
activity of a heterocyclic compound was next examined in
two models of stroke: (a) oxygen-glucose deprivation
(OGD) of cultured primary cerebrocortical neurons; and (b)
in the mouse, middle cerebral artery (MCA) occlusion
(MCAO)/reperfusion.
Promethazine was chosen as the compound representing
this class for three reasons. First, of the most potent inhibi-
tors of mPT, promethazine has one of the highest tolerated
doses in humans; although trifluoperazine is the strongest
mPT inhibitor, it is used in humans at doses 15-fold below
those of promethazine. Furthermore, trifluoperazine has
limited utility for long-term use in humans because of its
toxicity in nonneural tissues. Although irrelevant for the
short-term treatment required by stroke, this limitation
would present complications for the treatment of chronic
neurodegenerative diseases. Methiothepin, which is approx-
imately equivalent to promethazine in potency, has not
been used in humans. Second, promethazine is a well-toler-
ated drug with few adverse side effects, and, as opposed to
the heterocyclics, promethazine has comparatively minor
neurological side effects. We note that, from our experience
with minocycline (29), the in vitro assay can overestimate
the levels of drug necessary for protection in cell culture and
in vivo. Therefore, concentrations used in the cell assay
were chosen based on concentrations of promethazine shown
in the literature to be bioactive. Doses chosen for the in
vivo studies were also based on the literature. The dose used
was one half those shown to be nontoxic in an analysis in-
cluding cerebellar pathology. Doses were given at 12-h in-
tervals as it is known promethazine has an 8-h half-life in
mice. Third, promethazine does not appear to be a strong
PLA2 or calmodulin inhibitor and, thus, promethazine can
be used to demonstrate the independence of effects against
mPT induction and action on calmodulin or PLA2.
Promethazine Protects Cultured Primary Neurons from OGD.
OGD of primary cerebrocortical neurons is a widely used
cell culture model of stroke-related pathology. Prometha-
zine inhibited OGD-mediated neuronal death, as deter-
mined by reduction of LDH release into the media ( 65%
less release). Inhibition of neuronal death was observed at
submicromolar concentrations of promethazine (Fig. 3, 0.1
 M, P   0.05; 0.5  M, P   0.001). Caspase-3 activation
plays a key role in hypoxia/ischemia-mediated injury. To
gain insight into the mechanism of promethazine-mediated
neuroprotection, we evaluated whether this compound
could inhibit OGD-mediated caspase-3 activation. As ex-
pected from an mPT inhibitor, promethazine-treated neu-
rons exposed to OGD showed reduced caspase-3 activa-
tion, supporting the hypothesis that the drug interferes
with caspase-mediated cell death.
Follow-up studies have indicated that the tricyclic anti-
depressant nortriptyline, which also inhibits mPT (Fig. 1),
is also protective in this OGD model (unpublished data).
Figure 3. Promethazine protects primary cerebrocortical neurons from
OGD. LDH activity (A) and active caspase 3 (B) in the supernatant and
lysates, respectively, of control and OGD challenged primary cerebrocortical
neurons in the presence or absence of promethazine. *, P   0.05; **, P  
0.001. Neurotoxicity studies were conducted as described previously (60).Stavrovskaya et al. 217
Promethazine Reduces Infarct Size and Neurological Impair-
ment after MCAO-Reperfusion.  Because promethazine re-
duced OGD-mediated neuronal death, we evaluated
whether it could also ameliorate ischemic damage in vivo,
in which activation of the mPT and caspase-3 may play
roles. After MCAO, promethazine-treated mice showed a
53% reduction in lesion size compared with saline-treated
mice (Fig. 4 A, n   13, P   0.005). Both maximal infarct
size and variability of the injury were reduced by 65%.
Consistent with a reduction in ischemic damage, the neu-
rologic impairment score of promethazine-treated mice
was significantly improved 24 h after MCAO (Fig. 4 B,
P   0.05). Cerebral blood flow (measured by a laser-dop-
pler flowmeter) and systemic blood pressure did not differ
between the treated and control groups. As expected from
studies of other neuroprotectants, the neurologic score was
not different at 30 min after ischemia evaluation (Fig. 4 C
and references 61, 62). Protection of both neural function
and structure was consistent across all individual mice in
the analysis (Fig. 4 D, diagonal line emphasizes that all indi-
viduals are protected).
Follow-up studies have indicated that the tricyclic anti-
depressant nortriptyline, which also inhibits mPT (Fig. 1) is
also protective in this MCAO model (unpublished data).
Discussion
Defining the Pharmacophore. The heterocyclics and re-
lated compounds described here (HTPD) represent a series
of structurally related inhibitors that may help better under-
stand the mPT. SAR analysis, based on the final evidence
that 28 of 32 HTPD compounds are protective versus 10
out of 1,008 nonheterocyclics suggests that the HTPD
backbone’s activity is highly significant within the intact
screening set. Our data is most consistent with the active
pharmacophore being the basic class structure, rather than a
specific subclass as defined either clinically (e.g., antidepres-
sant vs. antipsychotic), biochemically (e.g., ability to in-
hibit PLA2), or structurally (e.g., noncarbon atom contain-
ing rings vs. tricyclic). There is a wide range of potency
for the heterocyclics (Fig. 2), but further SAR analysis is
currently limited by a lack of inactive compounds having
this basic structure in our current library. Of the group
studied, four compounds are not true heterocyclics (one
noncarbon atom in the “central” ring), suggesting the clas-
sical heterocyclic structure itself may not be mandatory.
Mefloquine has only two rings, suggesting the three-ring
backbone common in this class may be a reflection of the
set of compounds tested rather than an obligate structural
feature.
mPT in Stroke. These data are in accord with and sig-
nificantly extend findings of other groups who have pro-
vided evidence linking the mPT to excitotoxic and OGD
injury in cultured neurons (7, 69, 70) and to damage subse-
quent to ischemia-reperfusion in intact animals (6). The
Matsumoto et al. (6) and Khaspekov et al. (69) papers are of
particular note, as they used the N-Met-Val analogue of cy-
closporin A, which has been considered not to react with
calcineurin. Retrospective literature analysis also indicates
that several HTPD drugs had shown some protection
against ischemia or against mPT or mPT-like phenomena,
but that the existence of a structural class with a common
biochemical target (mitochondria) was not previously rec-
ognized, and has not been followed up clinically, possibly
due to the side effects of the specific agents tested. Specifi-
cally, our data allows us, for the first time, to pull together
15 yr of study of these agents to provide the first common
linkage of the HTPD compounds that crosses previously
recognized clinical, neurochemical target, and structural
bounds, and to provide a probable mechanism for their ac-
tions in vivo. Thus, as shown in Table I, the in vivo and
cell culture protection mediated by the HTPDs has been
replicated already, by at least 22 labs, in at least 10 HTPD
drugs in animal models of cerebral ischemia and related
Figure 4. Promethazine protects mice from
MCA occlusion/reperfusion. (A) Total stroke volume
in C57/Bl6 mice untreated and treated. P   0.005.
Means shown with SD to emphasize reduced vari-
ability of stroke volume in drug treatment, and
with standard error to show accuracy of population
estimate. (B) Neuro exam assessed at 24 h after rep-
erfusion of right MCA. Mean   SEM, P   0.05.
(C) Neuro exam assessed at 30 min after occlusion
of right MCA. Mean   SEM, P   1.0. (D) Stroke
Volume versus Neurologic Exam. Diagonal line
emphasizes that all treated individuals appear pro-
tected (left of line, 13 treated, 2 control; right of
line, 11 control). (inverted triangles) Promethazine
treated. (dots) Controls. n     13 in each group.
Middle cerebral artery occlusion/reperfusion studies
were conducted as described previously (references
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challenges and by at least 8 HTPD drugs in cell culture. We
note that agents have been shown to work both before and
after ischemia, and have been tested in mice, rats, and ger-
bils. Some isolated mitochondrial studies on HTPD agents
other than trifluoperazine and tamoxifen has also been pub-
lished. Histamine has been shown to cause swelling of liver
mitochondria, and antihistamines to retard it (68), but this
finding has not been examined further. Thioridazine has
been suggested to inhibit apoptosis and delay mPT induc-
tion by acting to reduce mitochondrial oxidative stress (71).
Thus, our data help explain and link a series of studies in
different research areas by providing a common mechanism
to explain the observations in these studies.
Our data also strengthen the case for mPT as a critical
event in the causative pathway of stroke-mediated cell death,
although some caveats still remain. Protection against mPT
Table I. Summary of Actions of HTPD Compounds
Drug name Drug class PT p-value CAL PLA2 Cerebral IR Cell
Trifluoperazine Antipsychotic 4.28   1.56  0.0001 20 ND 74, 75 76, 78
Methiothepin Other 3.61   0.79  0.0001 78 54
Promethazine Antihistaminic 3.56   0.97  0.0001 84 97 ab
Triflupromazine Antipsychotic 3.41   1.21  0.0001 70 75
Clomipramine Antidepressant 3.33   1.03  0.001 80 39 77, 79
Flufenazine Antihistaminic 3.32   1.54  0.01 73 72
Chlorprothixene Antipsychotic 3.30   1.24  0.01 111 94
Nortriptyline Antidepressant 3.16   1.12  0.01 77 81 c 78, 80
Promazine Antipsychotic 3.14   0.83  0.01 74 38
Thioridazine Antipsychotic 3.14   1.03  0.0001 84 76
Mefloquine Other 3.09   0.50  0.0001 37 45
Desipramine Antidepressant 3.08   0.95  0.0001 52 54 79, 81 80, 82
Chlorpromazine Antipsychotic 2.98   0.74  0.001 82 69 75, 81, 82 83, 84
Prochlorperazine Antipsychotic 2.96   1.05  0.0001 66 40
Propiomazine Other 2.88   0.89  0.01 111 47
Pimethixene Antihistaminic 2.79   0.99 0.001 26 33
Perphenazine Antipsychotic 2.74   0.42  0.01 103 58
Amitriptyline Antidepressant 2.64   0.77  0.0001 72 80 78, 80
Amoxepine Antidepressant 2.50   0.60  0.001 45 29
Maprotiline Antidepressant 2.42   0.56  0.001 50 10
Quinacrine Other 2.42   1.21  0.05 121 43 85–87 88, 89
Periciazine Antipsychotic 2.36   1.17  0.05 84 47
Ethopropazine Other 2.30   0.69  0.01 62 31
Mianserin Other 2.21   0.67  0.001 37 23 90, 92
Cyclobenzaprine Other 2.12   0.38  0.0001 87 80
Imipramine Antidepressant 2.10   0.50  0.01 ND 79 78, 80
Clozapine Antipsychotic 2.07   0.63  0.01 96 106 91, 93
Doxepin Antidepressant 1.68   0.56  0.05 68 87 79, 81
Loratadine Antihistaminic 1.04   0.35 NS 251 93
None identified
Thiothixene Antipsychotic 1.03   0.21 NS 71 115
Propantheline Other 0.84   0.39 NA 87 76
Pirenzepine Other 0.70   0.30 NA 485 45
Drug class as in Fig. 1 B.  PT presented as mean   SD as fold protection over control. Calmodulin (Cal) and phospholipase A2 (PLA2) as percent
control activity over untreated sample. Cerebral IR lists references for in vivo models are relevant for cerebral ischemia-reperfusion. Cell lists
references for cell culture models are relevant for cerebral ischemia/reperfusion.
aThis paper. 
bThis paper and unpublished data. 
cUnpublished data.
NS, P   0.05; NA, not applicable, mean   1.Stavrovskaya et al. 219
and in vivo protection against ischemia-reperfusion and
related events/challenges were shown to be qualitatively
correlated in at least 10 compounds (Table I). All of these
compounds displayed activity in at least one study in the
range of 3–20 mg/kg, consistent with relatively similar
dose dependence in in vitro assays of mPT inhibition. In
contrast, protection mediated by these agents does not cor-
relate with their ability to inhibit PLA2 or calmodulin and
cannot be attributed to either the clinical or structural class
of the mPT inhibitor (Fig. 1, Table I, and Fig. S3). By pro-
viding direct evidence consistent with mechanistic involve-
ment of mPT inhibition in the actions of these 10 com-
pounds, removing potential alternative explanations (e.g.,
PLA2 inhibition, calmodulin inhibition, and neurochemical
effects), and providing evidence that mPT inhibitors
structurally distinct from CsA are neuroprotective, our data
provide direct counter-arguments to each of the major
concerns raised previously (see Introduction) against mPT
playing a causative role in stroke-mediated damage. Re-
maining caveats include, for example, (a) the identification
of these compounds as mPT inhibitors is still based on
work in isolated liver mitochondria, the biochemically de-
fined system, but not the target tissue; (b) there are systems,
for example, the calcium overload model (72), that may
not involve mPT as a primary mediator; and (c) it is always
possible that a previously unrecognized system is the actual
target (e.g., the TRMP7 channels recently recognized to
contribute to anoxic cell death in some models; refer-
ence 73).
Potential Clinical Utility. The results reported here may
expand the potential clinical uses of HTPD drugs to pro-
tection against stroke, and set the stage for studies further
expanding their utility to other disorders. Additional stud-
ies are required; however, our data suggest that these agents
are potentially usable as long-term prophylactics (to reduce
damage from an event that occurs, not to prevent the
event) for individuals at risk for strokes and heart attacks
(e.g., patients undergoing carotid endarterectomy or who
have experienced a cardio- or cerebrovascular event). The
heterocyclics may also be appropriate for acute manage-
ment of stroke and heart attack as well as a component of
the clinical management of neurodegenerative disease. Fur-
ther retrospective analysis (see Online Supplemental Mate-
rial) showed two HTPD compounds at delayed mPT are
protective against spinal cord injury (trifluoperazine and
chlorpromazine) and three against myocardial and kidney
ischemia-reperfusion (trifluoperazine, chlorpromazine, and
quinacrine). Chlorpromazine has also been shown to pro-
tect against sepsis and liver toxicity/ischemia.
Although mPT involvement in chronic neurodegenera-
tive disorders remains unknown and controversial, the
common involvement of mitochondria in cell death path-
ways suggests that the HTPD drugs might be considered,
in future experiments, as potential candidates for long-term
use in individuals with neurodegenerative diseases that in-
volve cell death in the nervous system, including amyo-
trophic lateral sclerosis, and Parkinson’s, Alzheimer’s, and
Huntington’s diseases. Applicability in Huntington’s disease
is supported by data showing that 5–10 mg/kg prometha-
zine protects against striatal lesions in Lewis rats induced by
3-NP (unpublished data). Applicability in Parkinson’s dis-
ease is supported by data showing that promethazine (best
at 10 mg/kg) protects against striatal dopamine depletion
and neuron loss in the substantia nigra pars compacta in-
duced by MPTP (unpublished data). Both preclinical and
clinical testing will be required to determine whether these
drugs will be beneficial for these diseases.
These drugs appear to offer major advantages as clinical
mitochondrial protective agents. First, 31 out of the 32
compounds tested here are clinically available, and 27 are
clinically approved, suggesting the potential for rapid
movement into preclinical and/or clinical trials. Some of
these drugs have been used for five decades. Second, the
active drugs appear from their clinical uses and side effects
to cross the blood brain barrier (three possible exceptions
being cyclobenzaprine, mefloquine, and quinacrine). Third,
most are safe for long-term use, and many have only minor
side effects (a notable exception being the phenothiazine
trifluoperazine). Fourth, they are active in vitro and in vivo
at concentrations close to or within those that are achiev-
able in humans. The maximal therapeutic dose of pro-
methazine in humans is 3 mg/kg, and several have LD50 in
animals 5–10 times higher than promethazine with favor-
able safety profiles. Last, the many available classes of these
agents with differing side effects and clinical actions suggest
that a combination of agents, each one in a subclinical dose,
can be used to achieve mPT inhibition without inducing
unwanted effects. This work defines a structural family
suitable for further pharmacological optimization, comple-
menting the promise of available clinical therapies and
novel experimental reagents with a longer range promise of
even further optimized agents (e.g., for protection and for
probing mitochondrial involvement in cell death in isolated
systems, cultured cells, and in vivo). Although further pre-
clinical study is warranted, these finding suggest that these
clinically approved drugs will be candidates for human
study in stroke and neurodegeneration.
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